ADT + darolutamide extends overall survival in men with nmCRPC

According to a media release issued by Bayer a couple of days ago, the combination of androgen deprivation therapy (ADT) + darolutamide (Nubeqa) extends overall survival “significantly” in men with non-metastatic, castration-resistant prostate cancer (nmCRPC). … READ MORE …

Enzalutamide extends OS compared to an standard antiandrogen in ENZAMET trial, but …

The randomized, double-blind, Phase III ENZAMET trial was designed to investigate whether the combination of enzalutamide + standard androgen suppression had superior outcomes than a non-steroidal antiandrogen + standard androgen suppression in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …

Survival of men with metastatic, castration-resistant prostate cancer

There has been regular discussion here and elsewhere about the degree to which new forms of therapy have impacted patient survival since the original approval of docetaxel for treatment of metastatic, castration-resistant  prostate cancer (mCRPC). … READ MORE …

Men initially diagnosed with de novo metastatic prostate cancer are living longer

A newly published study entitled “Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study” is important … but needs to be interpreted with a significant degree of caution. … READ MORE …

Contemporary rates of overall and prostate cancer-specific mortality in Norway

A newly published study in the journal Urology (“the Gold journal”) has reported data on risk of death from prostate cancer and other causes among > 3,000 contemporary patients diagnosed with non-metastatic prostate cancer in 2004-2005. … READ MORE …

Metastasis-free survival as a surrogate endpoint in prostate cancer clinical trials

As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …

Nuts to the Daily Telegraph … and nuts for most of our readers!

Finally, we may have the perfect paper that illustrates the critical difference between overall mortality rates and cancer-specific cancer rates among men with prostate cancer, and how affecting one may have no effect whatsoever on the other! … READ MORE …

What does a very high PSA at diagnosis tell us?

Probably because of high level of research funding as a consequence of the Movember Foundation‘s initiatives, Australia is increasingly providing us with interesting data on the diagnosis, management, and outcomes of men with prostate cancer. … READ MORE …

Statin use and all-cause mortality among prostate cancer patients

Yet another study involving a large number of patients (this one from Taiwan) has again concluded that men with prostate cancer who take statins are less likely to die within a definable time period than men with prostate cancer who are not taking statins. … READ MORE …

Survival of men with mCRPC who receive no additional life-prolonging treatment

A new article in the Scandinavian Journal of Urology provides us with some insight — from relatively recent data — into the survival times of men with metastatic, castration-resistant prostate cancer (mCRPC) after prior treatment with androgen deprivation therapy (ADT) but who either decline or do not receive any further form of life-prolonging therapy. … READ MORE …

Does regular aspirin therapy improve survival of prostate cancer patients?

An open-access, full text article in the April issue of the Journal of Urology addresses long-standing questions about the impact of regular aspirin use on the long-term outcomes of men diagnosed with and treated for prostate cancer. … READ MORE

Non-prostate cancer-specific mortality rates in a cohort of > 3,000 patients

The issue of how long a man who is newly diagnosed with localized prostate cancer is likely to live before he dies a natural death from other causes is a crucial element in the decision whether to undergo treatment (and how aggressive that treatment may need to be). … READ MORE …

Badly judged and biased political spin from the European Association for Urology

According to a media release issued by the European Association of Urology on Saturday, just prior to the opening of their annual meeting in Milan, Italy, “Surgery is superior to radiotherapy in men with localized [prostate cancer].” This headline is not even justifiable based on the content of the media release. … READ MORE …

Median OS of men with CRPC may have doubled since 2003

A new article in European Urology suggests that the mean life expectancy for men participating in recent clinical trials and expanded access programs for new drugs for the treatment of chemotherapy-naive, castration-resistant prostate cancer (CRPC) — including metastatic and non-metastatic patients — is now just over 30 months. … READ MORE …

Overall survival among chemo-naive, mCRPC patients in the abiraterone acetate Phase III trial

There appears to be a great deal of confusion about the overall survival (OS) data related to the recent approval of abiraterone acetate for chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). Let’s try to really clarify this. … READ MORE …